Orpyx Names Lew Turnquist President

Technology Veteran to Lead Commercial Operations

Calgary, AB March 17, 2014 - Orpyx Medical Technologies Inc. announced today that Lew Turnquist has been appointed as president, effective immediately.  Turnquist has served in an advisory capacity at Orpyx since 2012 but will now lead its operations as the company executes its growth strategy to develop a strong portfolio of wearable pressure sensor technologies for healthcare applications.

"Lew is an optimal fit for Orpyx and we are profoundly honoured to have him join the team.  He shares our values and our focus on innovation," states Orpyx co-founder and chief executive, Dr. Breanne Everett.  "Lew has shown himself to be a leader throughout his career and has a proven track record of success, especially with scaling early-stage technology companies."

Turnquist has over 25 years of operational and transactional experience in technology companies.  He was most recently the senior managing partner at Kirchner Private Capital Group, a US-based boutique merchant bank, where he led the firm's transactions (M&A) and operational advisory practices.  Prior to this role, Turnquist led the growth or turnaround of several early-stage technology companies including: VX Technologies Inc., a 3D measurement product company; J-Commerce Inc., a retail point-of-sale software company; and Cell-Loc Inc., a wireless location technology and services company.

"I am truly excited to be a part of a dynamic, young company at the convergence of wearable technology, neuroplasticity, and the growing problem of diabetes," said Turnquist.  "It's an opportunity to change many people's lives for the better."

Dr. Everett will maintain an active role with the company as chief executive officer.

About Orpyx Medical Technologies:

Orpyx's primary intention is to address the world's growing epidemic of diabetes and its associated complications, most notably, lack of circulation, numbness, infection and ulcers in the feet, also known as peripheral neuropathy.  The diabetic foot ulcer is one of the most devastating side effects of diabetes, occurring in upwards of 15-25% of all diabetic patients over the course of their disease.  The inability to sense and respond to tissue damage can lead to the development of blisters and ulcers, which can lead to surgical ampuatation.  Orpyx was born out of a profound desire to find a preventative rather than reactionary solution to this problem.

For more information, please contact:

Stephanie Zakala
Marketing & Inside Sales Manager, Orpyx Medical Technologies Inc.

Download the PDF Press Release here.

Stephanie Zakala
Stephanie Zakala